Gruppo Italiano Trapianto di Midollo Osseo
Quick facts
Phase 3 pipeline
- Busulphan plus Cyclophosphamide · Oncology
Busulphan and cyclophosphamide are alkylating agents that damage DNA in cancer cells and bone marrow cells, used together as a myeloablative conditioning regimen prior to hematopoietic stem cell transplantation. - Busulphan plus Fludarabine · Oncology
Busulphan and Fludarabine together act as a myeloablative conditioning regimen that destroys bone marrow cells to prepare patients for hematopoietic stem cell transplantation.
Phase 2 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Gruppo Italiano Trapianto di Midollo Osseo portfolio CI brief
- Gruppo Italiano Trapianto di Midollo Osseo pipeline updates RSS
Frequently asked questions about Gruppo Italiano Trapianto di Midollo Osseo
What is Gruppo Italiano Trapianto di Midollo Osseo's pipeline?
Gruppo Italiano Trapianto di Midollo Osseo has 2 drugs in Phase 3, 2 in Phase 2, 0 in Phase 1. Late-stage candidates include Busulphan plus Cyclophosphamide, Busulphan plus Fludarabine.
Related
- Sector hub: All tracked pharma companies